Wall Street analyst estimates for Immunovant, Inc. (IMVT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.73 | ||
| 2026-08-06 | $-0.75 | $-0.63 | -19.3% |
| 2026-05-20 | $-0.73 | $-0.59 | -23.3% |
| 2026-02-06 | $-0.61 | $-0.72 | +15.3% |
| 2025-11-10 | $-0.73 | $-0.72 | -1.4% |
| 2025-08-11 | $-0.60 | $-0.69 | +13.0% |
| 2025-05-29 | $-0.64 | $-0.71 | +10.3% |
| 2025-02-06 | $-0.76 | $-0.73 | -4.1% |
Valuation Ratios
| Price / Book | 9.99 |
| Dividend Yield | 0.00% |
Price
| Price | $36.38 |
| Market Cap | $7.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACAD · AKRO · CRNX · DYN · KYMR · NAMS · PRAX
Explore sector: Healthcare · Biotechnology
More sections of IMVT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks